{"id":64610,"date":"2026-05-07T13:36:26","date_gmt":"2026-05-07T05:36:26","guid":{"rendered":"https:\/\/flcube.com\/?p=64610"},"modified":"2026-05-07T13:36:27","modified_gmt":"2026-05-07T05:36:27","slug":"cutia-therapeutics-secures-nmpa-approval-for-cu-30101-topical-anesthetic-cream-dermatology-specialist-expands-commercial-portfolio","status":"publish","type":"post","link":"https:\/\/flcube.com\/?p=64610","title":{"rendered":"Cutia Therapeutics Secures NMPA Approval for CU-30101 Topical Anesthetic Cream \u2013 Dermatology Specialist Expands Commercial Portfolio"},"content":{"rendered":"\n<p><strong>Cutia Therapeutics<\/strong> (<a href=\"https:\/\/www.google.com\/finance\/quote\/2487:HKG\">HKG: 2487<\/a>), a <strong>dermatology-focused specialty pharmaceutical company<\/strong>, announced that China&#8217;s <strong>National Medical Products Administration (NMPA)<\/strong> has approved the <strong>market approval filing<\/strong> for <strong>CU-30101<\/strong>, a <strong>topical lidocaine and tetracaine cream<\/strong>. The dual-anesthetic formulation delivers <strong>rapid and long-lasting anesthetic effects<\/strong> through the complementary pharmacokinetic properties of its active ingredients.<\/p>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-regulatory-milestone\">Regulatory Milestone<\/h2>\n\n\n\n<figure class=\"wp-block-table\"><table class=\"has-fixed-layout\"><thead><tr><th>Item<\/th><th>Detail<\/th><\/tr><\/thead><tbody><tr><td><strong>Agency<\/strong><\/td><td>NMPA (China)<\/td><\/tr><tr><td><strong>Approval Type<\/strong><\/td><td>Market approval filing approved<\/td><\/tr><tr><td><strong>Product<\/strong><\/td><td>CU-30101 (topical lidocaine, tetracaine cream)<\/td><\/tr><tr><td><strong>Indication<\/strong><\/td><td>Topical anesthesia for dermatological procedures<\/td><\/tr><tr><td><strong>Developer<\/strong><\/td><td>Cutia Therapeutics (HKG: 2487)<\/td><\/tr><tr><td><strong>Approval Date<\/strong><\/td><td>7 May 2026<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-product-profile-amp-mechanism-of-action\">Product Profile &amp; Mechanism of Action<\/h2>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Dual-Anesthetic Formulation:<\/strong> Combines <strong>lidocaine<\/strong> (amide-type local anesthetic) and <strong>tetracaine<\/strong> (amino acid ester local anesthetic)<\/li>\n\n\n\n<li><strong>Rapid Onset:<\/strong> <strong>Lidocaine disperses faster<\/strong> and provides <strong>wider coverage<\/strong> for immediate anesthetic effect<\/li>\n\n\n\n<li><strong>Prolonged Duration:<\/strong> <strong>Tetracaine is more lipophilic<\/strong> than lidocaine and <strong>concentrates in the epidermal stratum corneum<\/strong>, delivering sustained anesthesia<\/li>\n\n\n\n<li><strong>Synergistic Effect:<\/strong> The unique combination leverages complementary pharmacokinetic properties to achieve both <strong>rapid onset<\/strong> and <strong>extended duration<\/strong> of action<\/li>\n<\/ul>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-clinical-evidence-amp-competitive-positioning\">Clinical Evidence &amp; Competitive Positioning<\/h2>\n\n\n\n<figure class=\"wp-block-table\"><table class=\"has-fixed-layout\"><thead><tr><th>Aspect<\/th><th>CU-30101 (Cutia)<\/th><th>Pliaglis (Taro Pharmaceuticals)<\/th><\/tr><\/thead><tbody><tr><td><strong>Formulation<\/strong><\/td><td>Lidocaine + tetracaine cream<\/td><td>Lidocaine + tetracaine cream<\/td><\/tr><tr><td><strong>Clinical Data<\/strong><\/td><td>China Phase III study demonstrating <strong>comparable efficacy<\/strong> and <strong>good safety profile<\/strong><\/td><td>Globally marketed reference product<\/td><\/tr><tr><td><strong>Market Status<\/strong><\/td><td>NMPA approval secured for Chinese market<\/td><td>Commercially available globally<\/td><\/tr><tr><td><strong>Development Strategy<\/strong><\/td><td>Local clinical trial program with direct comparator<\/td><td>Established global commercial presence<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n<p>The <strong>China Phase III study<\/strong> directly compared CU-30101 against <strong>Taro Pharmaceuticals&#8217; Pliaglis<\/strong>, establishing <strong>non-inferior efficacy<\/strong> and confirming a <strong>favorable safety profile<\/strong> for the Cutia-developed formulation.<\/p>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-market-opportunity-amp-strategic-impact\">Market Opportunity &amp; Strategic Impact<\/h2>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Dermatology Procedure Growth:<\/strong> China&#8217;s aesthetic and medical dermatology markets continue rapid expansion, driving demand for effective topical anesthetics that enhance patient comfort during procedures.<\/li>\n\n\n\n<li><strong>Local Manufacturing Advantage:<\/strong> As a <strong>locally developed and manufactured<\/strong> product, CU-30101 benefits from potential pricing advantages and streamlined supply chain logistics compared to imported alternatives.<\/li>\n\n\n\n<li><strong>Portfolio Diversification:<\/strong> This approval represents a strategic expansion of Cutia&#8217;s commercial portfolio beyond its core dermatology therapeutics into the <strong>adjunctive care segment<\/strong>.<\/li>\n\n\n\n<li><strong>Competitive Landscape:<\/strong> Entry into the topical anesthetic market positions Cutia to capture share from both <strong>imported products<\/strong> like Pliaglis and <strong>generic alternatives<\/strong>, leveraging its dermatology expertise and established commercial infrastructure.<\/li>\n<\/ul>\n\n\n\n<p>The approval enables Cutia to address a well-established market need with a clinically validated product that maintains the therapeutic benefits of the reference formulation while potentially offering improved accessibility for Chinese healthcare providers and patients.<\/p>\n\n\n\n<p><strong>Forward\u2011Looking Statements<\/strong><br>This brief contains forward-looking statements regarding regulatory approvals, market opportunities, and commercial expectations for CU-30101. Actual results may differ due to risks including market adoption, competitive dynamics, and pricing pressures.<a href=\"https:\/\/flcube.com\/\">-Fineline Info &amp; Tech<\/a><\/p>\n\n\n\n<div data-wp-interactive=\"core\/file\" class=\"wp-block-file\"><object data-wp-bind--hidden=\"!state.hasPdfPreview\" hidden class=\"wp-block-file__embed\" data=\"https:\/\/flcube.com\/wp-content\/uploads\/2026\/05\/2026050700028_c.pdf\" type=\"application\/pdf\" style=\"width:100%;height:600px\" aria-label=\"Embed of 2026050700028_c.\"><\/object><a id=\"wp-block-file--media-66e68f8c-8e28-473a-8175-051a070c5b68\" href=\"https:\/\/flcube.com\/wp-content\/uploads\/2026\/05\/2026050700028_c.pdf\">2026050700028_c<\/a><a href=\"https:\/\/flcube.com\/wp-content\/uploads\/2026\/05\/2026050700028_c.pdf\" class=\"wp-block-file__button wp-element-button\" download aria-describedby=\"wp-block-file--media-66e68f8c-8e28-473a-8175-051a070c5b68\">Download<\/a><\/div>\n","protected":false},"excerpt":{"rendered":"<p>Cutia Therapeutics (HKG: 2487), a dermatology-focused specialty pharmaceutical company, announced that China&#8217;s National Medical Products&#8230;<\/p>\n","protected":false},"author":1,"featured_media":0,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"googlesitekit_rrm_CAownpewDA:productID":"","_jetpack_memberships_contains_paid_content":false,"footnotes":"","jetpack_publicize_message":"","jetpack_publicize_feature_enabled":true,"jetpack_social_post_already_shared":true,"jetpack_social_options":{"image_generator_settings":{"template":"highway","default_image_id":0,"font":"","enabled":false},"version":2}},"categories":[7,11],"tags":[450,1221,15],"class_list":["post-64610","post","type-post","status-publish","format-standard","hentry","category-company","category-drug","tag-cutia-therapeutics","tag-hkg-2487","tag-product-approvals"],"yoast_head":"<!-- This site is optimized with the Yoast SEO Premium plugin v23.6 (Yoast SEO v27.5) - https:\/\/yoast.com\/product\/yoast-seo-premium-wordpress\/ -->\n<title>Cutia Therapeutics Secures NMPA Approval for CU-30101 Topical Anesthetic Cream \u2013 Dermatology Specialist Expands Commercial Portfolio - Insight, China&#039;s Pharmaceutical Industry<\/title>\n<meta name=\"description\" content=\"Cutia Therapeutics (HKG: 2487), a dermatology-focused specialty pharmaceutical company, announced that China&#039;s National Medical Products Administration (NMPA) has approved the market approval filing for CU-30101, a topical lidocaine and tetracaine cream. The dual-anesthetic formulation delivers rapid and long-lasting anesthetic effects through the complementary pharmacokinetic properties of its active ingredients.\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/flcube.com\/?p=64610\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Cutia Therapeutics Secures NMPA Approval for CU-30101 Topical Anesthetic Cream \u2013 Dermatology Specialist Expands Commercial Portfolio\" \/>\n<meta property=\"og:description\" content=\"Cutia Therapeutics (HKG: 2487), a dermatology-focused specialty pharmaceutical company, announced that China&#039;s National Medical Products Administration (NMPA) has approved the market approval filing for CU-30101, a topical lidocaine and tetracaine cream. The dual-anesthetic formulation delivers rapid and long-lasting anesthetic effects through the complementary pharmacokinetic properties of its active ingredients.\" \/>\n<meta property=\"og:url\" content=\"https:\/\/flcube.com\/?p=64610\" \/>\n<meta property=\"og:site_name\" content=\"Insight, China&#039;s Pharmaceutical Industry\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/profile.php?id=61566606313834\" \/>\n<meta property=\"article:published_time\" content=\"2026-05-07T05:36:26+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2026-05-07T05:36:27+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg\" \/>\n\t<meta property=\"og:image:width\" content=\"2560\" \/>\n\t<meta property=\"og:image:height\" content=\"1894\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/jpeg\" \/>\n<meta name=\"author\" content=\"Fineline Cube\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:description\" content=\"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Fineline Cube\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"2 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=64610#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=64610\"},\"author\":{\"name\":\"Fineline Cube\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\"},\"headline\":\"Cutia Therapeutics Secures NMPA Approval for CU-30101 Topical Anesthetic Cream \u2013 Dermatology Specialist Expands Commercial Portfolio\",\"datePublished\":\"2026-05-07T05:36:26+00:00\",\"dateModified\":\"2026-05-07T05:36:27+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=64610\"},\"wordCount\":432,\"commentCount\":0,\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"keywords\":[\"Cutia Therapeutics\",\"HKG: 2487\",\"Product approvals\"],\"articleSection\":[\"Company\",\"Drug\"],\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"CommentAction\",\"name\":\"Comment\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=64610#respond\"]}],\"copyrightYear\":\"2026\",\"copyrightHolder\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"}},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=64610\",\"url\":\"https:\\\/\\\/flcube.com\\\/?p=64610\",\"name\":\"Cutia Therapeutics Secures NMPA Approval for CU-30101 Topical Anesthetic Cream \u2013 Dermatology Specialist Expands Commercial Portfolio - Insight, China&#039;s Pharmaceutical Industry\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\"},\"datePublished\":\"2026-05-07T05:36:26+00:00\",\"dateModified\":\"2026-05-07T05:36:27+00:00\",\"description\":\"Cutia Therapeutics (HKG: 2487), a dermatology-focused specialty pharmaceutical company, announced that China's National Medical Products Administration (NMPA) has approved the market approval filing for CU-30101, a topical lidocaine and tetracaine cream. The dual-anesthetic formulation delivers rapid and long-lasting anesthetic effects through the complementary pharmacokinetic properties of its active ingredients.\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=64610#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=64610\"]}]},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=64610#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/flcube.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Cutia Therapeutics Secures NMPA Approval for CU-30101 Topical Anesthetic Cream \u2013 Dermatology Specialist Expands Commercial Portfolio\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"name\":\"Insight, China's Pharmaceutical Industry\",\"description\":\"Fineline Insights, Pharma Clarity\",\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/flcube.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\",\"name\":\"Fineline Infomation and Technology\",\"alternateName\":\"Fineline Info & Tech\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"contentUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"width\":2560,\"height\":1894,\"caption\":\"Fineline Infomation and Technology\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\"},\"sameAs\":[\"https:\\\/\\\/www.facebook.com\\\/profile.php?id=61566606313834\"]},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\",\"name\":\"Fineline Cube\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"caption\":\"Fineline Cube\"},\"sameAs\":[\"https:\\\/\\\/flcube.com\"],\"url\":\"https:\\\/\\\/flcube.com\\\/?author=1\"}]}<\/script>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"Cutia Therapeutics Secures NMPA Approval for CU-30101 Topical Anesthetic Cream \u2013 Dermatology Specialist Expands Commercial Portfolio - Insight, China&#039;s Pharmaceutical Industry","description":"Cutia Therapeutics (HKG: 2487), a dermatology-focused specialty pharmaceutical company, announced that China's National Medical Products Administration (NMPA) has approved the market approval filing for CU-30101, a topical lidocaine and tetracaine cream. The dual-anesthetic formulation delivers rapid and long-lasting anesthetic effects through the complementary pharmacokinetic properties of its active ingredients.","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/flcube.com\/?p=64610","og_locale":"en_US","og_type":"article","og_title":"Cutia Therapeutics Secures NMPA Approval for CU-30101 Topical Anesthetic Cream \u2013 Dermatology Specialist Expands Commercial Portfolio","og_description":"Cutia Therapeutics (HKG: 2487), a dermatology-focused specialty pharmaceutical company, announced that China's National Medical Products Administration (NMPA) has approved the market approval filing for CU-30101, a topical lidocaine and tetracaine cream. The dual-anesthetic formulation delivers rapid and long-lasting anesthetic effects through the complementary pharmacokinetic properties of its active ingredients.","og_url":"https:\/\/flcube.com\/?p=64610","og_site_name":"Insight, China&#039;s Pharmaceutical Industry","article_publisher":"https:\/\/www.facebook.com\/profile.php?id=61566606313834","article_published_time":"2026-05-07T05:36:26+00:00","article_modified_time":"2026-05-07T05:36:27+00:00","og_image":[{"width":2560,"height":1894,"url":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","type":"image\/jpeg"}],"author":"Fineline Cube","twitter_card":"summary_large_image","twitter_description":"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM","twitter_misc":{"Written by":"Fineline Cube","Est. reading time":"2 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/flcube.com\/?p=64610#article","isPartOf":{"@id":"https:\/\/flcube.com\/?p=64610"},"author":{"name":"Fineline Cube","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a"},"headline":"Cutia Therapeutics Secures NMPA Approval for CU-30101 Topical Anesthetic Cream \u2013 Dermatology Specialist Expands Commercial Portfolio","datePublished":"2026-05-07T05:36:26+00:00","dateModified":"2026-05-07T05:36:27+00:00","mainEntityOfPage":{"@id":"https:\/\/flcube.com\/?p=64610"},"wordCount":432,"commentCount":0,"publisher":{"@id":"https:\/\/flcube.com\/#organization"},"keywords":["Cutia Therapeutics","HKG: 2487","Product approvals"],"articleSection":["Company","Drug"],"inLanguage":"en-US","potentialAction":[{"@type":"CommentAction","name":"Comment","target":["https:\/\/flcube.com\/?p=64610#respond"]}],"copyrightYear":"2026","copyrightHolder":{"@id":"https:\/\/flcube.com\/#organization"}},{"@type":"WebPage","@id":"https:\/\/flcube.com\/?p=64610","url":"https:\/\/flcube.com\/?p=64610","name":"Cutia Therapeutics Secures NMPA Approval for CU-30101 Topical Anesthetic Cream \u2013 Dermatology Specialist Expands Commercial Portfolio - Insight, China&#039;s Pharmaceutical Industry","isPartOf":{"@id":"https:\/\/flcube.com\/#website"},"datePublished":"2026-05-07T05:36:26+00:00","dateModified":"2026-05-07T05:36:27+00:00","description":"Cutia Therapeutics (HKG: 2487), a dermatology-focused specialty pharmaceutical company, announced that China's National Medical Products Administration (NMPA) has approved the market approval filing for CU-30101, a topical lidocaine and tetracaine cream. The dual-anesthetic formulation delivers rapid and long-lasting anesthetic effects through the complementary pharmacokinetic properties of its active ingredients.","breadcrumb":{"@id":"https:\/\/flcube.com\/?p=64610#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/flcube.com\/?p=64610"]}]},{"@type":"BreadcrumbList","@id":"https:\/\/flcube.com\/?p=64610#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/flcube.com\/"},{"@type":"ListItem","position":2,"name":"Cutia Therapeutics Secures NMPA Approval for CU-30101 Topical Anesthetic Cream \u2013 Dermatology Specialist Expands Commercial Portfolio"}]},{"@type":"WebSite","@id":"https:\/\/flcube.com\/#website","url":"https:\/\/flcube.com\/","name":"Insight, China's Pharmaceutical Industry","description":"Fineline Insights, Pharma Clarity","publisher":{"@id":"https:\/\/flcube.com\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/flcube.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/flcube.com\/#organization","name":"Fineline Infomation and Technology","alternateName":"Fineline Info & Tech","url":"https:\/\/flcube.com\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/","url":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","contentUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","width":2560,"height":1894,"caption":"Fineline Infomation and Technology"},"image":{"@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/www.facebook.com\/profile.php?id=61566606313834"]},{"@type":"Person","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a","name":"Fineline Cube","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","caption":"Fineline Cube"},"sameAs":["https:\/\/flcube.com"],"url":"https:\/\/flcube.com\/?author=1"}]}},"jetpack_publicize_connections":[],"jetpack_featured_media_url":"","jetpack_sharing_enabled":true,"_links":{"self":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/64610","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=64610"}],"version-history":[{"count":1,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/64610\/revisions"}],"predecessor-version":[{"id":64612,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/64610\/revisions\/64612"}],"wp:attachment":[{"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=64610"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=64610"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=64610"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}